PRVL · Prevail Therapeutics Inc

-

Please sign in to comment on PRVL

1 Comment

Admin

4 years ago

Prevail Therapeutics Inc is currently in a long term uptrend where the price is trading 48.2% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Prevail Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 8.4% to $-19M since the same quarter in the previous year.

Finally, its free cash flow grew by 11.6% to $-17M since the same quarter in the previous year.

Based on the above factors, Prevail Therapeutics Inc gets an overall score of 4/5.

Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
ISIN	US74140Y1010
Industry	Biotechnology

Dividend Yield	0.0%
Beta	nan
Market Cap	788M
PE Ratio	None
Target Price	23.63

ABOUT

Prevail Therapeutics Inc

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

PRVL · Prevail Therapeutics Inc

-

Prevail Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Prevail Therapeutics Inc using a moving average strategy